Exploring rituximab for the treatment of refractory myasthenia gravis: a single-centre experience
Background Myasthenia gravis (MG) is a rare autoimmune disorder that affects neuromuscular transmission, leading to muscle weakness. While most patients respond to standard treatments, approximately 15% remain refractory, prompting interest in alternative therapies. This study examined the use of ri...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2025-11-01
|
| Seri Bilgileri: | BMJ Neurology Open |
| Online Erişim: | https://neurologyopen.bmj.com/content/7/2/e001130.full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|